Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) shares gained 13.4% after the company confirmed it will make a presentation on the effect of oral and parenteral administration of anti-eotaxin-1 antibodies at The Liver Meeting 2017. The company will also showcase its novel personalized therapy for immune-associated liver diseases.
Experiments carried out on an animal models of immune-mediated hepatitis have shown that blocking eotaxin-1 can have a profound impact on the development of hepatic inflammation. According to Immune Pharmaceuticals Inc. (NASDAQ:IMNP), anti-eotaxin has proved to be reliable in the blocking of liver injuries, whether administered orally or parentally.
“Our collaboration with Dr. Ilan has been fruitful and yielded results suggesting that blocking eotaxin-1 can have a beneficial effect in liver diseases. We will continue to explore the development of bertilimumab in liver diseases, further to our strategic business plan of focusing our resources on this first-in-class antibody,” said CEO, Elliot Maza.
IMNP Stock Performance
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has been trading in a downtrend for the better part of the year. The stock is down by more than 50% for the year after struggling to rise above $2 on two attempts.
The company’s poor performance has caught the attention of the NASDAQ Stock Market. The listing agency has warned that the stock faces the risk of being delisted if the company’s stock equity drops below $2.5 million. The company has also been taken to task for not meeting the alternative compliance standards relating to market value of listed securities of $35 million or net income of $500,000.
Phase Trial Boost
Late last month, the stock received a boost after Immune Pharmaceuticals Inc. (NASDAQ:IMNP) reported positive results from a Phase 2 clinical trial for moderate to severe bullous pemphigoid. Clinical trial results indicate that six subjects under study experienced a decline in the Bullous Pemphigoid Disease Area Index.
All Subjects achieved a greater than 50% reduction in BPDAO Total Activity Score. Four of the six subjects had a 90% reduction as Bertilimumab remained well tolerated in all six subjects with no serious adverse events.
“If bertilimumab can substantially reduce or perhaps even eliminate the need for systemic corticosteroids in the treatment of bullous pemphigoid and their significant toxicity in this elderly population, it will be a major step forward in the management of what is the most common blistering disease,” said Dr. Neil Korman.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $IMNP and receive breaking news on other hot stocks by signing up for our free newsletter!